Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Patent
1996-04-03
1999-01-12
Rories, Charles C. P.
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
536 231, 536 243, 536 2431, 536 2432, 536 2433, 435 6, 435375, 514 44, C07H 2100, A61K 3170, A61K 3174, A61K 4800
Patent
active
058592296
ABSTRACT:
The present invention provides a new antisense oligonucleotides for the treatment of premature labor, premature rupture of the fetal membranes, premature cervical dilation and effacement, preeclampsia, endometriosis, rheumatoid arthritis, ARDs, and glomerulitis. The drugs are antisense oligonucleotides which attenuate the expression of either the mRNA encoding the cyclooxygenase protein or the mRNA encoding the thromboxane A.sub.2 synthase protein. Once the mRNA encoding for cyclooxygenase is inhibited, the production of cyclooxygenase is inhibited thereby inhibiting the production of the cyclooxygenase products such as prostaglandins and thromboxane. Thus, the antisense oligonucleotides provide novel therapy for the treatment of diseases involving cyclooxygenase products, prostaglandins and thromboxane metabolism. Such diseases include immunological, reproductive, cardiovascular, dermatologic, central nervous system disorders in which the release of cyclooxygenase products effects the genesis and progression of the disease. A second object of the invention is to provide new reagents for the research and study of the diseases involving cyclooxygenase products.
REFERENCES:
patent: 5112868 (1992-05-01), Cetenko
patent: 5219874 (1993-06-01), Faull et al.
patent: 5543297 (1996-08-01), Cromlish et al.
"Molecular Cloning of Human Platelet Thromboxane A Synthase", Yokoyama, et al. Biochem & Biophys. Res. Comm., vol. 178, No. 3, 1991, pp. 1479-1484.
J. Milligan et al. J. Med. Chem. 36(14) ('93) 1923-37.
B. Monia et al. J. Biol. Chem. 267 (28) ('92) 19954-62.
W. James Antiviral Chem & Chemosler. 2(4) ('91) 191-214.
E. Uhlumann et al. Chem. Rev. 90(4) ('90) 543-84.
B. Tseng et al. Cancer Gene Therapy 1 (1) ('94) 65-71.
C. Siena et al. Science 261 ('93) 1004-12.
P. Weszermann et al. Biomed. Biochim Acra. 48('89) 85-93.
E. Uhlmann et al. Chemical Reviews, vol. 90#4 (Jun. '90) pp. 543-584.
B. Tseng et al. Cancer Gene Therapy, vol. #1 (Mar. '94) pp. 65-71.
C. Stein et al. Science, vol. 261 (20 Aug. '93) pp. 1004-1012.
R. Weiss. Science News, vol. 139 (Feb. 16, 1991) pp. 108-109.
P. Wessermann et al. Biowed. Biochim. Aeta, vol. 48 ('89) pp. 85-93.
D. DeWitt et al. J. Biol Chem., vol. 265 #9 (25 Mar. '90) pp. 5192-5198.
M. K. O'Banion PNAS, vol. 89 (Jun. '92) pp. 4888-4892.
G.Funk et al. FASEB Journals, vol. 5 ('91) pp. 2304-2312.
T. H1. et al. PNAS, vol. 89 (Aug. 1992) pp. 7384-7388.
Rories Charles C. P.
The Ohio State University
LandOfFree
Antisense oligonucleotides to suppress eicosanoid formation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense oligonucleotides to suppress eicosanoid formation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense oligonucleotides to suppress eicosanoid formation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1517816